Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Retains JMP to Help with Lab Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure this week said that it has retained the financial services firm JMP Securities to help it increase business for its DiagnoCure Oncology Laboratories.

In a statement, Yves Fradet, president and chief medical officer of DiagnoCure, added that JMP will help the company "determine the most effective method to roll out our colorectal cancer disease management program."

Based in West Chester, Penn., the oncology lab is a subsidiary of DiagnoCure and launched its Previstage GCC Colorectal Cancer Staging Test in 2008. The test is currently undergoing additional testing for confirmation of its clinical utility, DiagnoCure said.

The laboratory recently received approval from New York state to use the Previstage test on commercial samples originating in New York, opening up a significant market for the firm, it said at the time.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.